1. Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling. (October 2020) Authors: Bendell, J.; Ulahannan, S.; Koczywas, M.; Brahmer, J.; Capasso, A.; Eckhardt, S.G.; Gordon, M.; McCoach, C.; Nagasaka, M.; Ng, K.; Pacheco, J.; Riess, J.; Spira, A.; Steuer, C.; Dua, R.; Chittivelu, S.; Masciari, S.; Wang, Z.; Wang, X.; Ou, S.H. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗